A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer

BACKGROUND: Adding bevacizumab to chemotherapy for recurrent, persistent or metastatic cervical cancer significantly improved overall survival (primary endpoint), progression-free survival and overall response rate in the randomized Phase III GOG-0240 trial. However, data for bevacizumab-containing...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiyama, Toru, Mizuno, Mika, Aoki, Yoichi, Sakurai, Manabu, Nishikawa, Tadaaki, Ueda, Eisuke, Tajima, Kosei, Takeshima, Nobuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421579/
https://www.ncbi.nlm.nih.gov/pubmed/27803033
http://dx.doi.org/10.1093/jjco/hyw143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421579/
https://www.ncbi.nlm.nih.gov/pubmed/27803033
http://dx.doi.org/10.1093/jjco/hyw143

Ejemplares similares